Bristol-Myers Squibb Partners To Expand Diabetes Franchise In China
This article was originally published in PharmAsia News
With Glucophage and Onglyza already on the market, BMS plans to launch more products in China through partnerships to gain a share of the world’s largest diabetes market.
You may also be interested in...
The Danish biotech has partnerships with major players in several therapeutic areas, including a successful tie-up with Sanofi, and is looking to partner some of its other pipeline programs as well.
Bristol suggests FDA has had a change of heart on the evolving filing package for diabetes drug dapagliflozin. Meanwhile, the company sees no additional U.S. regulatory hurdles ahead for the eagerly awaited, novel oral anticoagulant Eliquis.
In acquiring Amylin at a hefty premium, Bristol-Myers Squibb and its partner AstraZeneca are highly optimistic about prospects for Amylin’s GLP-1 franchise, and also hope to leverage their existing infrastructure as their fledgling diabetes franchise struggles to meet expectations.